Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT06777719RecruitingPhase 1
A study of immune cells to prevent kidney rejection
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
NantesAges 18–99 - NCT06583083RecruitingPhase 2
Sintilimab plus chemo vs chemo alone for advanced ENKTL lymphoma
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT07410520RecruitingPhase 2
New drug combo for brain lymphoma
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Nanjing, JiangsuAges 18 years+ - NCT06900010RecruitingPhase 2
CM336 for Autoimmune Blistering Disease
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
JinanAges 18 years+ - NCT07356713RecruitingPhase 1
Finding the right dose of EXL-111 for healthy volunteers
This trial tests a new drug called EXL-111 in healthy people to find the safest and best dose for future studies. It may help people with allergies if the drug proves effective.
Adelaide, South AustraliaAges 18–55 - NCT04047576RecruitingPhase 2/Phase 3
Sirolimus for unknown-cause retroperitoneal scarring
This trial tests sirolimus to treat idiopathic (unknown-cause) retroperitoneal fibrosis, a condition where scar tissue forms in the belly behind the kidneys. You may be considered if imaging and blood tests suggest active inflammation, and if you’re able to safely take the study medicine and return for follow-up.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT07388407Recruiting
Genetics of leflunomide for rheumatoid arthritis
This study looks at how your genes might affect how well leflunomide works for rheumatoid arthritis. It is for Pakistani adults who are starting or recently started leflunomide, and will help doctors understand who might respond best.
Islamabad, Punjab ProvinceAges 20–65 - NCT07400302RecruitingPhase 2
Sintilimab plus chemo for resected mucosal melanoma
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
Changchun, JilinAges 18 years+ - NCT06414278Recruiting
Spotting early thinking and memory changes with immunotherapy
This study looks at how a special type of immunotherapy called CAR-T therapy might affect your thinking skills, memory, and ability to focus. By checking on patients early and often, the team hopes to find simple ways to detect and manage these side effects sooner.
Minneapolis, MinnesotaAges 18 years+ - NCT07381738RecruitingPhase 2
Cord blood transplant for Epstein-Barr virus diseases
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT06887322Enrolling by invitationPhase 1/Phase 2
Herbal cream for plaque psoriasis
This study tests an herbal cream made from Ciplukan (a plant) on plaque psoriasis. If you are an adult with mild-to-moderate psoriasis and are not already using other treatments, this trial may help find a gentler option.
Bandung, West JavaAges 18–60 - NCT05954507Recruiting
PET/MRI scan to assess heart risk in sarcoidosis
This study checks whether a special heart scan called PET/MRI can predict how sarcoidosis may affect your heart. It may help doctors better estimate heart risk and plan follow-up based on scan findings.
CréteilAges 18 years+ - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT05670262Recruiting
Study vitamin D and gut bacteria in childhood allergies
This study looks at how gut bacteria (microbiome) and vitamin D levels in newborns may influence whether children develop allergies. It starts with newborn babies and aims to better understand what early factors could predict allergic diseases.
TaichungAges birth–1 year - NCT06551194Recruiting
Studying hard-to-treat inflammatory bowel disease
This study looks at people with inflammatory bowel disease (IBD) that is hard to manage. Researchers want to understand how common it is, how it is treated, and what happens over time.
MilanAges 18–69 - NCT06918808RecruitingPhase 2
Stem cell therapy for Crohn's fistula healing
This trial tests if a special stem cell treatment (called DB-3Q bmMSC-EVs) can help heal fistulas caused by Crohn's disease. It's for people who have already tried other treatments and still have actively draining fistulas.
Aurora, ColoradoAges 18–75 - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06090253Recruiting
Sport exercise program for healthy aging over 60
This trial tests a program that uses sports and exercise to help people over 60 stay healthy and active. It looks at both how well the program works and how easy it is to put into practice.
Hong KongAges 60 years+ - NCT07571304Recruiting
Dual-Task Training for Teens with Multiple Sclerosis
This study tests whether doing two things at once while exercising (like walking while counting) helps teenagers with multiple sclerosis improve balance, coordination, and daily functioning. The goal is to see if this type of training is better than standard exercise for managing MS symptoms.
IstanbulAges 12–18 - NCT06488950RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
ShanghaiAges 18–75 - NCT06338995RecruitingPhase 3
Lebrikizumab for nasal polyps and sinusitis
This trial tests a new injectable medicine (lebrikizumab) for people with chronic sinusitis and nasal polyps that steroid treatments haven't controlled. It aims to reduce polyp size and improve breathing, smell, and congestion.
Birmingham, AlabamaAges 12 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.